These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

256 related items for PubMed ID: 3988970

  • 21. View from the nation's capital.
    Romansky MA.
    J Clin Psychopharmacol; 1985 Feb; 5(1):51-2. PubMed ID: 2982923
    [No Abstract] [Full Text] [Related]

  • 22. View from the Nation's Capital.
    Romansky MA.
    J Clin Psychopharmacol; 1984 Feb; 4(1):52-4. PubMed ID: 6096407
    [No Abstract] [Full Text] [Related]

  • 23. Drug development. Orphan drug windfalls?
    Gershon D.
    Nature; 1992 Jan 30; 355(6359):381. PubMed ID: 1734267
    [No Abstract] [Full Text] [Related]

  • 24. Lucrative niches: how drugs for rare diseases became lifeline for companies.
    Anand G.
    Wall St J (East Ed); 2005 Nov 15; ():A1, A18. PubMed ID: 16502531
    [No Abstract] [Full Text] [Related]

  • 25. The future of orphan drug development.
    Woodcock J.
    Clin Pharmacol Ther; 2012 Aug 15; 92(2):146-8. PubMed ID: 22814657
    [No Abstract] [Full Text] [Related]

  • 26. [Orphan drugs].
    Galeffi C.
    Ann Ist Super Sanita; 1991 Aug 15; 27(2):341-3. PubMed ID: 1661568
    [Abstract] [Full Text] [Related]

  • 27. EMEA approves OGS drug rejected by FDA.
    Mitchell P.
    Nat Biotechnol; 2002 Sep 15; 20(9):858-9. PubMed ID: 12205490
    [No Abstract] [Full Text] [Related]

  • 28. Orphan drug development for the treatment of rare chronic diseases.
    Moore ES.
    Tex Hosp; 1988 Jul 15; 44(2):20-1. PubMed ID: 10288218
    [No Abstract] [Full Text] [Related]

  • 29. HHS defends expanded 340B drug discounts.
    Lee J.
    Mod Healthc; 2014 Jun 16; 44(24):9. PubMed ID: 25137989
    [No Abstract] [Full Text] [Related]

  • 30. [The European Union begins its road to orphan drugs].
    Dal-Ré R, Avendaño C.
    Med Clin (Barc); 1998 May 02; 110(15):576-8. PubMed ID: 9650202
    [No Abstract] [Full Text] [Related]

  • 31. View from the Nation's Capital. Investigational new drug (IND) and new drug application (NDA).
    Romansky MA.
    J Clin Psychopharmacol; 1983 Jun 02; 3(3):193-4. PubMed ID: 6680405
    [No Abstract] [Full Text] [Related]

  • 32. The Orphan Drug Act Revisited.
    Thomas S, Caplan A.
    JAMA; 2019 Mar 05; 321(9):833-834. PubMed ID: 30768155
    [No Abstract] [Full Text] [Related]

  • 33. View from the Nation's Capital. New drug application (NDA) and investigational new drug (IND) regulations.
    Romansky MA.
    J Clin Psychopharmacol; 1983 Dec 05; 3(6):380-3. PubMed ID: 6680409
    [No Abstract] [Full Text] [Related]

  • 34. Generic drugs: the stalling game.
    Consum Rep; 2001 Jul 05; 66(7):36-40. PubMed ID: 11725791
    [Abstract] [Full Text] [Related]

  • 35. Biotech and pharma face more costly clinical trials.
    Brower V.
    Nat Biotechnol; 1998 Aug 05; 16(8):714. PubMed ID: 9702762
    [No Abstract] [Full Text] [Related]

  • 36. Knowledge is power: legislative control of drug industry trade secrets.
    O'Reilly JT.
    Spec Law Dig Health Care (Mon); 1987 May 05; 8(15):7-31. PubMed ID: 10281981
    [No Abstract] [Full Text] [Related]

  • 37. Should off-label drug use be off-the-table?
    Rivkees SA.
    J Pediatr Endocrinol Metab; 2007 Feb 05; 20(2):171-2. PubMed ID: 17396432
    [No Abstract] [Full Text] [Related]

  • 38. Orphan economics: the downside of supplyside pharmacology.
    Samson K.
    Ann Neurol; 2008 Sep 05; 64(3):A13-6. PubMed ID: 18825669
    [No Abstract] [Full Text] [Related]

  • 39. The challenges of orphan drugs and orphan diseases: real and imagined.
    Hudson I, Breckenridge A.
    Clin Pharmacol Ther; 2012 Aug 05; 92(2):151-3. PubMed ID: 22814659
    [Abstract] [Full Text] [Related]

  • 40. Drug shortage crisis resolution.
    Duffy E.
    J Pharm Pract; 2012 Dec 05; 25(6):619-20. PubMed ID: 23222856
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.